SGNPDL-1V is under clinical development by Seagen and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SGNPDL-1V’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SGNPDL-1V is under development for the treatment of advanced solid tumors including non-small cell lung cancer (NSCLC), ovarian cancer, melanoma, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer, esophageal squamous cell carcinoma (SCC). The drug candidate comprises of PD-(L)1 antibody conjugated with monomethyl auristatin E (MMAE). The drug candidate targets cells expressing PD-(L)1 and developed based on antibody-drug conjugate (ADC) technology. It is administered through intravenous route.
Seagen, formerly Seattle Genetics, is a biotechnology company that discovers, develops, and markets monoclonal antibody-based therapies for the treatment of cancer. It markets antibody-drug conjugates (ADCs), including Adcetris (brentuximab vedotin), for the treatment of Hodgkin’s lymphoma, T-cell lymphomas, and CD30 expressing lymphomas; Padcevtm (enfortumab vedotin-ejfv) for metastatic urothelial cancers; Tukysa (tucatinib) for the treatment of metastatic HER2-positive breast cancers, and Tivdak (tisotumab vedotin-tftv) for the treatment of certain metastatic cervical cancers. The company’s pipeline consists of novel therapies for addressing the unmet medical needs of blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology and SEA technology which targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.
For a complete picture of SGNPDL-1V’s drug-specific PTSR and LoA scores, buy the report here.